Journal for ImmunoTherapy of Cancer (Nov 2021)
533 An open label Phase IA/IB study for safety, pharmacokinetics (PK), and efficacy of ONC 392 as a single agent and in combination with Pembrolizumab in advanced solid tumors
Abstract
No abstracts available.